Wall Street brokerages forecast that GW Pharmaceuticals PLC (NASDAQ:GWPH) will post earnings of ($1.39) per share for the current quarter, Zacks reports. Two analysts have made estimates for GW Pharmaceuticals PLC’s earnings. The lowest EPS estimate is ($2.12) and the highest is ($0.09). GW Pharmaceuticals PLC reported earnings of ($0.89) per share in the same quarter last year, which indicates a negative year over year growth rate of 56.2%. The firm is scheduled to announce its next quarterly earnings results on Monday, December 4th.

According to Zacks, analysts expect that GW Pharmaceuticals PLC will report full-year earnings of ($5.99) per share for the current financial year, with EPS estimates ranging from ($6.66) to ($5.04). For the next year, analysts forecast that the firm will report earnings of ($6.43) per share, with EPS estimates ranging from ($6.96) to ($6.13). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow GW Pharmaceuticals PLC.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.73) by ($0.34). The business had revenue of $3.14 million for the quarter, compared to the consensus estimate of $2.10 million. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. During the same quarter last year, the firm posted ($0.05) EPS.

GWPH has been the subject of a number of research reports. Maxim Group reiterated a “buy” rating and issued a $135.00 price objective on shares of GW Pharmaceuticals PLC in a report on Thursday, May 25th. Zacks Investment Research downgraded GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Thursday, July 6th. BidaskClub upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. ValuEngine upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Finally, Evercore ISI initiated coverage on GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They issued an “outperform” rating and a $154.00 price objective for the company. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. GW Pharmaceuticals PLC has an average rating of “Buy” and an average target price of $148.55.

Shares of GW Pharmaceuticals PLC (GWPH) traded down 2.83% during mid-day trading on Friday, reaching $105.93. 375,143 shares of the company’s stock were exchanged. The firm’s market capitalization is $2.68 billion. GW Pharmaceuticals PLC has a one year low of $92.65 and a one year high of $137.88. The stock has a 50-day moving average of $106.70 and a 200 day moving average of $110.29.

Several large investors have recently modified their holdings of the company. Royal Bank of Canada increased its holdings in shares of GW Pharmaceuticals PLC by 0.4% during the second quarter. Royal Bank of Canada now owns 4,240 shares of the biopharmaceutical company’s stock valued at $424,000 after acquiring an additional 18 shares in the last quarter. Creative Planning increased its holdings in shares of GW Pharmaceuticals PLC by 1.4% during the second quarter. Creative Planning now owns 2,532 shares of the biopharmaceutical company’s stock valued at $254,000 after acquiring an additional 35 shares in the last quarter. IHT Wealth Management LLC increased its holdings in shares of GW Pharmaceuticals PLC by 18.0% during the second quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 100 shares in the last quarter. Advisor Group Inc. increased its holdings in shares of GW Pharmaceuticals PLC by 10.7% during the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 145 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of GW Pharmaceuticals PLC by 8.5% during the second quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 162 shares in the last quarter. Hedge funds and other institutional investors own 75.07% of the company’s stock.

WARNING: “GW Pharmaceuticals PLC (GWPH) Expected to Post Earnings of -$1.39 Per Share” was originally published by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/13/gw-pharmaceuticals-plc-gwph-expected-to-post-earnings-of-1-39-per-share.html.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.